CytRx Corporation (NASDAQ: CYTR) today announced that an investment-community conference call has been scheduled for Wednesday, September 6, 2006, beginning at 4:15 p.m. Eastern Time (1:15 p.m. Pacific Time) to discuss CytRx’s August 29 announcement of its receipt of $24.5 million in a non-dilutive royalty agreement with the privately funded ALS Charitable Remainder Trust to fund continued development of CytRx’s lead small molecule drug candidate arimoclomol for the treatment of amyotrophic lateral sclerosis (ALS or Lou Gehrig’s disease). The ALS Charitable Remainder Trust, under which The Greater Los Angeles Chapter of The ALS Association (ALSA-GLAC) is the charitable remainder beneficiary, will receive a one percent royalty payment from potential worldwide sales of arimoclomol for the treatment of ALS. A copy of the press release can be found on the CytRx Web site at www.cytrx.com.
